ITUB20169994A1 - Nuove forme cristalline di farmaci immunomodulatori - Google Patents

Nuove forme cristalline di farmaci immunomodulatori

Info

Publication number
ITUB20169994A1
ITUB20169994A1 ITUB2016A009994A ITUB20169994A ITUB20169994A1 IT UB20169994 A1 ITUB20169994 A1 IT UB20169994A1 IT UB2016A009994 A ITUB2016A009994 A IT UB2016A009994A IT UB20169994 A ITUB20169994 A IT UB20169994A IT UB20169994 A1 ITUB20169994 A1 IT UB20169994A1
Authority
IT
Italy
Prior art keywords
crystalline forms
new crystalline
immunomodulatory drugs
immunomodulatory
drugs
Prior art date
Application number
ITUB2016A009994A
Other languages
English (en)
Inventor
Alessandro Gagnoni
Antonio Germani
Original Assignee
Phf Sa
Fis Fabbrica Italiana Sintetici Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phf Sa, Fis Fabbrica Italiana Sintetici Spa filed Critical Phf Sa
Priority to ITUB2016A009994A priority Critical patent/ITUB20169994A1/it
Priority to EP16801233.4A priority patent/EP3397626B1/en
Priority to PCT/EP2016/078726 priority patent/WO2017121530A1/en
Priority to JP2017556876A priority patent/JP2018515477A/ja
Priority to US15/560,723 priority patent/US10155740B2/en
Publication of ITUB20169994A1 publication Critical patent/ITUB20169994A1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
ITUB2016A009994A 2016-01-14 2016-01-14 Nuove forme cristalline di farmaci immunomodulatori ITUB20169994A1 (it)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ITUB2016A009994A ITUB20169994A1 (it) 2016-01-14 2016-01-14 Nuove forme cristalline di farmaci immunomodulatori
EP16801233.4A EP3397626B1 (en) 2016-01-14 2016-11-24 Process for the purification of immunomodulatory drug pomalidomide using a co-crystal with gentisic acid
PCT/EP2016/078726 WO2017121530A1 (en) 2016-01-14 2016-11-24 Crystal forms of immunomodulatory drug pomalidomide and co-crystal with gentisic acid
JP2017556876A JP2018515477A (ja) 2016-01-14 2016-11-24 免疫調節薬の新規な結晶形
US15/560,723 US10155740B2 (en) 2016-01-14 2016-11-24 Crystal forms of immunomodulatory drug pomalidomide and co-crystal with gentisic acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITUB2016A009994A ITUB20169994A1 (it) 2016-01-14 2016-01-14 Nuove forme cristalline di farmaci immunomodulatori

Publications (1)

Publication Number Publication Date
ITUB20169994A1 true ITUB20169994A1 (it) 2017-07-14

Family

ID=55861097

Family Applications (1)

Application Number Title Priority Date Filing Date
ITUB2016A009994A ITUB20169994A1 (it) 2016-01-14 2016-01-14 Nuove forme cristalline di farmaci immunomodulatori

Country Status (5)

Country Link
US (1) US10155740B2 (it)
EP (1) EP3397626B1 (it)
JP (1) JP2018515477A (it)
IT (1) ITUB20169994A1 (it)
WO (1) WO2017121530A1 (it)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014170909A2 (en) 2013-04-01 2014-10-23 Hetero Research Foundation Process for pomalidomide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050962A1 (en) * 2009-10-29 2011-05-05 Ratiopharm Gmbh Acid addition salts of lenalidomide
CN103626738A (zh) * 2013-12-23 2014-03-12 重庆泰濠制药有限公司 一种泊马度胺晶型及其制备方法
WO2014160690A1 (en) * 2013-03-26 2014-10-02 Celgene Corporation Solid forms comprising 4-amino-2-(2.6-dioxopiperidine-3-yl) isoindoline-1,3-dione and a coformer, compositions and methods of use thereof
WO2014170909A2 (en) * 2013-04-01 2014-10-23 Hetero Research Foundation Process for pomalidomide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2701709B1 (fr) * 1993-02-17 1995-04-07 Rhone Poulenc Rorer Sa Forme purifiée de streptograminés, sa préparation et les compositions pharmaceutiques qui la contiennent.
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
JP5069905B2 (ja) * 2003-01-21 2012-11-07 アプテュイト （ウエスト ラファイエット）、エルエルシー 新規な共結晶化
ME01513B (me) 2005-06-30 2014-04-20 Celgene Corp Postupak dobijanja spojeva 4-amin0-2-(2,6-dioksopiperidin-3-il)izoindolin-1,3-diona
WO2013012485A2 (en) 2011-07-19 2013-01-24 Amplio Pharma, Llc Novel crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
WO2013126326A1 (en) 2012-02-21 2013-08-29 Celgene Corporation Solid forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, compositions and methods of use thereof
CN103288797B (zh) 2013-05-17 2016-03-02 宁波百思佳医药科技有限公司 一种用亚砜类溶剂纯化Pomalidomide的方法
CN103275062B (zh) * 2013-05-17 2016-04-13 宁波百思佳医药科技有限公司 一种Pomalidomide的纯化方法
PT107166B (pt) * 2013-09-16 2018-12-28 Hovione Farm S A Síntese e engenharia de partículas de cocristais

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050962A1 (en) * 2009-10-29 2011-05-05 Ratiopharm Gmbh Acid addition salts of lenalidomide
WO2014160690A1 (en) * 2013-03-26 2014-10-02 Celgene Corporation Solid forms comprising 4-amino-2-(2.6-dioxopiperidine-3-yl) isoindoline-1,3-dione and a coformer, compositions and methods of use thereof
WO2014170909A2 (en) * 2013-04-01 2014-10-23 Hetero Research Foundation Process for pomalidomide
CN103626738A (zh) * 2013-12-23 2014-03-12 重庆泰濠制药有限公司 一种泊马度胺晶型及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VISHWESHWAR P ET AL: "Crystal engineering of pharmaceutical co-crystals from polymorphic active pharmaceutical ingredients", CHEMICAL COMMUNICATIONS - CHEMCOM; [6015D], ROYAL SOCIETY OF CHEMISTRY, GB, no. 36, 28 September 2005 (2005-09-28), pages 4601 - 4603, XP002565290, ISSN: 1359-7345, DOI: 10.1039/B501304F *

Also Published As

Publication number Publication date
JP2018515477A (ja) 2018-06-14
EP3397626B1 (en) 2020-10-28
US10155740B2 (en) 2018-12-18
WO2017121530A1 (en) 2017-07-20
EP3397626A1 (en) 2018-11-07
US20180099944A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
MA46972A (fr) Forme polymorphe de sépiaptérine
HK1252845A1 (zh) 勞拉替尼游離碱的結晶形式
MA47596A (fr) Formes cristallines du dérivé 4-pyrimidinesulfamide aprocitentan
IL263050B (en) History of Subtirum
ES2841649T5 (es) Composición farmacéutica
MA46567A (fr) Formes cristallines de l'éravacycline
FR3023290B1 (fr) Derives de flavaglines
FR3059559B1 (fr) Descendeur autobloquant
MA46266A (fr) Formes cristallines
MA48944A (fr) Forme cristalline de n-butyldéoxygalactonojirimycine
IT201700090690A1 (it) Procedimento e macchina per la produzione di forme di dosaggio
DK3522773T3 (da) Intrafascikulært elektrodeimplantat
ITUB20169994A1 (it) Nuove forme cristalline di farmaci immunomodulatori
MA43166A (fr) Formulation de fviii
EP3337479A4 (en) NOVEL POLYMORPH OF DOLUTEGRAVIR AND SALTS FROM IT
ITUA20161550A1 (it) Procedimento per la produzione di RNA
IT201700050223A1 (it) Procedimento per la preparazione di dexlansoprazolo cristallino
IT201700025286A1 (it) Forme cristalline di vinpocetina cloridrato
MA44471A (fr) Forme cristalline
MA52458A (fr) Nouvelles formes cristallines
DK3529231T3 (da) Krystallinsk diethylamintetrathiomolybdat og farmaceutiske anvendelser deraf
ITUB20161079A1 (it) Procedimento per la preparazione di sofosbuvir
UA34109S (uk) Ковдра
UA34108S (uk) Ковдра
IT201600129753A1 (it) Struttura di calcio-balilla